Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET (EVERLAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01567488
Recruitment Status : Completed
First Posted : March 30, 2012
Last Update Posted : January 3, 2018
Information provided by (Responsible Party):
Grupo Espanol de Tumores Neuroendocrinos

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : September 1, 2014
  Study Completion Date : June 7, 2017